- Home
- TILE vs OCS Comparison
TILE vs OCS Comparison
Compare TILE & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TILE
- OCS
- Stock Information
- Founded
- TILE 1973
- OCS 2003
- Country
- TILE United States
- OCS Switzerland
- Employees
- TILE N/A
- OCS N/A
- Industry
- TILE Home Furnishings
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- TILE Consumer Discretionary
- OCS Health Care
- Exchange
- TILE Nasdaq
- OCS Nasdaq
- Market Cap
- TILE 1.2B
- OCS 1.0B
- IPO Year
- TILE N/A
- OCS N/A
- Fundamental
- Price
- TILE $21.72
- OCS $18.74
- Analyst Decision
- TILE Buy
- OCS Strong Buy
- Analyst Count
- TILE 1
- OCS 3
- Target Price
- TILE $30.00
- OCS $35.33
- AVG Volume (30 Days)
- TILE 334.3K
- OCS 25.8K
- Earning Date
- TILE 08-01-2025
- OCS 08-26-2025
- Dividend Yield
- TILE 0.18%
- OCS N/A
- EPS Growth
- TILE 44.62
- OCS N/A
- EPS
- TILE 1.46
- OCS N/A
- Revenue
- TILE $1,323,328,000.00
- OCS $847,333.00
- Revenue This Year
- TILE $5.19
- OCS $18.70
- Revenue Next Year
- TILE $4.91
- OCS $1,059.78
- P/E Ratio
- TILE $15.17
- OCS N/A
- Revenue Growth
- TILE 5.41
- OCS N/A
- 52 Week Low
- TILE $14.13
- OCS $10.79
- 52 Week High
- TILE $27.34
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- TILE 60.60
- OCS 43.61
- Support Level
- TILE $20.74
- OCS $18.87
- Resistance Level
- TILE $22.26
- OCS $19.75
- Average True Range (ATR)
- TILE 0.55
- OCS 0.38
- MACD
- TILE 0.12
- OCS -0.13
- Stochastic Oscillator
- TILE 75.89
- OCS 10.62
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.